Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAID trial of Compound Danshen Dripping Pills for coronary microvascular disease
ChiCTR2600134911Phase 4Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Compound Danshen in Coronary Small Vessel Disease (CMD) (2 arms), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Change from baseline in maximal coronary flow reserve of the left anterior descending artery at 12 months. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
Compound Danshen
03
Conditions
Coronary Small Vessel Disease (CMD)
Beyond the preview
Go deeper on ChiCTR2600134911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134911.